Chong Kun Dang Pharmaceutical Corp. (185750) AI Stock Analysis

Chong Kun Dang Pharmaceutical Corp.

(Korea Exchange:185750)

Select Model

Rating:57Neutral

Price Target:$63,446.00▲(0.55% Upside)

Action:initiatedcoverage

Date:10/28/26

The score is held back primarily by weaker financial quality (margin compression and persistently negative free cash flow) and bearish technicals (below key moving averages with negative MACD). These are partially offset by relatively attractive valuation (low P/E), which provides some downside support.

Positive Factors

Strong Revenue GrowthThe substantial TTM revenue increase indicates strong demand or successful commercialization across the company’s pharmaceutical portfolio. If this expansion is sustained, it can broaden the revenue base, support pipeline investment, and improve operating scale over the next several quarters.

Negative Factors

Margin CompressionThe sharp decline in gross and net margins reduces the quality of the company’s revenue growth and leaves less profit available from each unit of sales. Persistent compression could weaken reinvestment capacity and make earnings more sensitive to costs or product mix.

Chong Kun Dang Pharmaceutical Corp. (185750) vs. SPDR S&P 500 ETF (SPY)

Market Cap: KRW 831.41B
Dividend Yield: 0.79%
Average Volume (3M): 20.06K
Price to Earnings (P/E): 10.5
Beta (1Y): 0.12
Revenue Growth: 7.15%
EPS Growth: 29.88%
Country: KR
Employees: 2,304
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Chong Kun Dang Pharmaceutical Corp. Business Overview & Revenue Model

Company Description

Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetics, antiviruses, beta-blockers, anti-hyperlipidemia, and others. The company was...

Chong Kun Dang Pharmaceutical Corp. Financial Statement Overview

Summary

Strong TTM revenue growth (~251%) is offset by meaningful profitability compression (gross margin ~40% to ~29%; net margin ~12.7% to ~4.5%). Balance sheet is reasonably sound with moderate leverage (equity ~1.02T vs. debt ~0.44T) but debt-to-equity has risen (~0.43 TTM vs. ~0.21 in 2024). The biggest drag is cash flow: despite improved operating cash flow (~123B TTM), free cash flow remains negative (~-69B TTM), reducing financial flexibility.

Income Statement

62Positive

Balance Sheet

66Positive

Cash Flow

38Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.78T	1.69T	1.59T	1.67T	1.49T	1.34T
Gross Profit	517.58B	517.23B	532.61B	662.20B	542.64B	495.82B
EBITDA	123.97B	125.37B	150.10B	287.62B	137.61B	112.71B
Net Income	79.47B	77.83B	109.07B	212.52B	80.95B	42.72B
Balance Sheet
Total Assets	1.87T	1.80T	1.46T	1.40T	1.12T	1.05T
Cash, Cash Equivalents and Short-Term Investments	329.30B	346.50B	302.17B	365.07B	155.86B	187.33B
Total Debt	437.44B	367.76B	188.15B	219.76B	235.74B	237.05B
Total Liabilities	847.85B	793.94B	562.39B	586.79B	503.59B	480.89B
Stockholders Equity	1.02T	1.00T	893.97B	815.69B	622.39B	566.01B
Cash Flow
Free Cash Flow	-69.22B	-73.49B	-1.81B	249.35B	14.67B	-38.94B
Operating Cash Flow	123.26B	67.36B	64.29B	318.16B	67.73B	12.90B
Investing Cash Flow	-299.64B	-245.28B	3.73B	-171.31B	-65.38B	-90.81B
Financing Cash Flow	219.20B	166.96B	-63.11B	-43.70B	-16.34B	85.14B

Chong Kun Dang Pharmaceutical Corp. Technical Analysis

Technical Analysis SentimentNegative

Last Price63100.00

Price Trends

50DMA66084.00Negative

100DMA67403.00Negative

200DMA76743.00Negative

Market Momentum

MACD-983.65Positive

RSI41.50Neutral

STOCH19.74Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:185750, the sentiment is Negative. The current price of 63100.00 is below the 20-day moving average (MA) of 64935.00, below the 50-day MA of 66084.00, and below the 200-day MA of 76743.00, indicating a bearish trend. The MACD of -983.65 indicates Positive momentum. The RSI at 41.50 is Neutral, neither overbought nor oversold. The STOCH value of 19.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:185750.

Chong Kun Dang Pharmaceutical Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

KR:185750 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KR:001060	71Outperform	KRW 555.42B	5.49	―	2.83%	10.50%	96.29%
KR:003850	68Neutral	KRW 702.03B	9.47	―	1.93%	6.39%	29.21%
KR:003090	62Neutral	KRW 617.86B	3.25	―	1.32%	4.55%	116.82%
KR:185750	57Neutral	KRW 831.41B	10.46	―	0.79%	7.15%	29.88%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
KR:006280	54Neutral	KRW 1.49T	-29.78	―	1.15%	9.73%	-167.75%

* General Sector Average

Performance Comparison

KR:185750 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
KR:185750	Chong Kun Dang Pharmaceutical Corp.	63100.00	-19812.28	-23.90%
KR:001060	JW Pharmaceutical Corporation	23000.00	-645.26	-2.73%
KR:003090	Daewoong Co., Ltd.	15110.00	-6496.22	-30.07%
KR:003850	Boryung Corporation	8310.00	-461.66	-5.26%
KR:006280	GC Biopharma Corp.	130200.00	798.34	0.62%
KR:086450	DongKook Pharmaceutical Co., Ltd.	23450.00	6091.61	35.09%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

Chong Kun Dang Pharmaceutical Corp. AI Stock Analysis